Selux Diagnostics, Inc., a Boston, MA-based biotech startup whose mission is to combat superbug infections and fight antimicrobial resistance (AMR), raised an additional $48 in funding.
The round was led by RA Capital Management with participation from Northpond Ventures, Sands Capital, and Schooner Capital.
The company intends to use the funds to launch the next phase of commercialization of the Selux Next Generation Phenotyping (NGP) System within the United States.
Led by Steve Lufkin, CEO, Selux Diagnostics is accelerating the selection of personalized antimicrobial therapy for all infectious disease patients. This additional funding follows the company’s announcement of their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, which enables them to provide single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
The Selux NGP System is a rapid Antibiotic Susceptibility Testing (AST) platform that can deliver same-day AST results which will transform patient care and reduce the overreliance on broad spectrum antibiotics, a major factor in the increase of superbugs.
This platform has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); and Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800013C.
FinSMEs
01/04/2024